Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multidimensional integrated assessment of neurological and immunological patterns to test the efficacy and response to Ozanimod in multiple sclerosis
2021-005860-24Phase 4Terminated
- Sponsor
- Fondazione Santa Lucia IRCCS
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of ozanimod in multiple sclerosis (MS), sponsored by Fondazione Santa Lucia IRCCS. Primary endpoint: Innate immune mediated inflammation in MS patients. Started Sep 2022; status: terminated.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2021-005860-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005860-24.